RE:RE:RVX in Bioworld ArticleThe therapeutic potential of topoisomerase 1 inhibition is summed up in the last sentence of the discussion of the Science research
article.
"
Our results suggest that a Top1 inhibition therapy could be useful in many instances, such as in pandemics and many congenital deficiencies, whereby an overt immune response is acutely induced."
However, this has only been used in cell culture and mice. It has a long way to go both pre-clinical and clinical before being considered a serious clinical agent.
I don't know why the BioWorld write up mentioned Resverlogix specifically since there are several other BET inhibitors, as well as many other classes of chromatin-modifying drugs, in clinical trials. Maybe because RVX-208 and other Resverlogix/Zenith BET inhibitors have documented anti-inflammatory properties as well as effects on the acute phase response/complement cascade?
BearDownAZ